Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Operations: 2016-2024

Historic Cash from Operations for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to -$78.2 million.

  • Dianthus Therapeutics' Cash from Operations fell 43.67% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.5 million, marking a year-over-year decrease of 74.98%. This contributed to the annual value of -$78.2 million for FY2024, which is 112.09% down from last year.
  • Per Dianthus Therapeutics' latest filing, its Cash from Operations stood at -$78.2 million for FY2024, which was down 112.09% from -$36.9 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Cash from Operations registered a high of -$29.1 million during FY2022, and its lowest value of -$78.2 million during FY2024.
  • In the last 3 years, Dianthus Therapeutics' Cash from Operations had a median value of -$36.9 million in 2023 and averaged -$48.0 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 51.17% in 2022, then slumped by 112.09% in 2024.
  • Yearly analysis of 5 years shows Dianthus Therapeutics' Cash from Operations stood at -$64.0 million in 2020, then increased by 7.02% to -$59.5 million in 2021, then skyrocketed by 51.17% to -$29.1 million in 2022, then declined by 26.80% to -$36.9 million in 2023, then plummeted by 112.09% to -$78.2 million in 2024.